TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32434234

Group type: EXPERIMENTAL
Intervention: Combined administration of topical and intravenous tranexamic acid (TXA)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (TXA) alone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid (TXA) alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined administration of IA and IV TXA
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined administration of topical and IV TXA
Number of subjects: 94

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 94
Study: 35912144

Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (routine nursing care)
Number of subjects: 126
Study: 33938413

Group type: EXPERIMENTAL
Intervention: Free and self-paid COVID-19 vaccination intention
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Engagement in COVID-19-related work
Number of subjects: 2064
Study: 32036584

Group type: EXPERIMENTAL
Intervention: Personalized exercise programme
Number of subjects: 66
Study: 34504288

Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise training (6 weeks, 3 days a week, including warm-up, trunk stabilization, and breathing exercises under physiotherapist supervision)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (only informed about the importance of exercise for one session)
Number of subjects: 41
Study: 33264809

Group type: EXPERIMENTAL
Intervention: ERAS protocol (POST group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care (PRE group)
Number of subjects: 144
Study: 35900221

Group type: EXPERIMENTAL
Intervention: Small group discussions
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control
Number of subjects: 404
Study: 33407156

Group type: COMPARATOR
Intervention: Dexmedetomidine (bolus infusion of 0.5 μg/kg over 10 min, 0.4 μg/kg/h continuous infusion)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h continuous infusion)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lidocaine plus Dexmedetomidine (combination of both interventions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lidocaine plus Dexmedetomidine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 160
Study: 32500139

Group type: EXPERIMENTAL
Intervention: ICE FALCON method
Number of subjects: 0
Study: 34028496

Group type: EXPERIMENTAL
Intervention: Antiseizure medication (ASM) discontinued at discharge
Number of subjects: 303

Group type: COMPARATOR
Intervention: Antiseizure medication (ASM) maintained at discharge
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Antiseizure medication (ASM) discontinued
Number of subjects: 303

Group type: COMPARATOR
Intervention: Antiseizure medication (ASM) maintained
Number of subjects: 303
Study: 33225960

Group type: EXPERIMENTAL
Intervention: IFNβ-1a (44 mcg, three times per week for 2 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 126
Study: 35131090

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33755136

Group type: EXPERIMENTAL
Intervention: PADIT risk score (1 unit increase)
Number of subjects: 51623

Group type: EXPERIMENTAL
Intervention: Prior CIED infection
Number of subjects: 51623

Group type: EXPERIMENTAL
Intervention: PADIT score and history of prior CIED infection
Number of subjects: 51623
Study: 32139550

Group type: EXPERIMENTAL
Intervention: Educational intervention (two 45 min training sessions on serrated polyp detection)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Untrained endoscopists (control group)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Educational intervention (first training session)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Educational intervention (second training session)
Number of subjects: 117
Study: 33988917

Group type: EXPERIMENTAL
Intervention: Structured contraceptive counselling
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Routine counselling
Number of subjects: 1364
Study: 32485945

Group type: COMPARATOR
Intervention: Continuous Training (CT) - 30–60 min, 70–80% peak heart rate, three times per week for eight weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) - 5–10 near maximal 30 s sprints, 3 min recovery, three times per week for eight weeks
Number of subjects: 25
Study: 34110881

Group type: EXPERIMENTAL
Intervention: QuitBet (digital social game with a $30 bet for 28 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: QuitBet (digital social game)
Number of subjects: 50
Study: 34747022

Group type: EXPERIMENTAL
Intervention: VIPP‐SD intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dummy intervention (Control)
Number of subjects: 66
Study: 36242868

Group type: EXPERIMENTAL
Intervention: Emergency cervical cerclage (ECC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 11
Study: 32758047

Group type: EXPERIMENTAL
Intervention: e‐version of the chronic kidney disease patient awareness questionnaire
Number of subjects: 217
Study: 35214712

Group type: EXPERIMENTAL
Intervention: sIPV (three lots)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: IPV (control)
Number of subjects: 1300
Study: 32404343

Group type: EXPERIMENTAL
Intervention: Adalimumab taper (every 3 weeks) for 36 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Adalimumab withdrawal (placebo) for 36 weeks
Number of subjects: 122
Study: 36018230

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 978

Group type: COMPARATOR
Intervention: adalimumab 40 mg
Number of subjects: 978
Study: 32621362

Group type: EXPERIMENTAL
Intervention: Monopolar 2 MHz radiofrequency device
Number of subjects: 19
Study: 32580032

Group type: EXPERIMENTAL
Intervention: lifestyle plus metformin
Number of subjects: 3060

Group type: COMPARATOR
Intervention: lifestyle only
Number of subjects: 3060
Study: 35040913

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 4876

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4876
Study: 32369630

Group type: EXPERIMENTAL
Intervention: In situ decompression
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 117
Study: 35987997

Group type: EXPERIMENTAL
Intervention: Lavender fragrance
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no lavender)
Number of subjects: 34
Study: 33504809

Group type: EXPERIMENTAL
Intervention: CD8+ natural killer cells (NK8+) signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate markers of the NK8+ signature in peripheral blood leucocytes
Number of subjects: 0
Study: 32758713

Group type: EXPERIMENTAL
Intervention: Child victimization
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Harsh punishment
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Caregiver depression
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Caregiver resilience
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Positive parenting
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 385
Study: 36385206

Group type: EXPERIMENTAL
Intervention: Intervention group (deprescribing intervention)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (standard prescribing practices)
Number of subjects: 404
Study: 33958779

Group type: EXPERIMENTAL
Intervention: BP index variants from genome‐wide association studies (GWASs)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 430
Study: 32499069

Group type: EXPERIMENTAL
Intervention: 3.0-mm intramedullary headless compression screw
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.0-mm T-plate
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 oblique 1.0-mm Kirschner wires
Number of subjects: 30
Study: 35440464

Group type: EXPERIMENTAL
Intervention: sintilimab with chemotherapy (cisplatin plus paclitaxel)
Number of subjects: 659

Group type: COMPARATOR
Intervention: placebo with chemotherapy (cisplatin plus paclitaxel)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: sintilimab with chemotherapy (cisplatin plus 5‐fluorouracil)
Number of subjects: 659

Group type: COMPARATOR
Intervention: placebo with chemotherapy (cisplatin plus 5‐fluorouracil)
Number of subjects: 659
Study: 32492135

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (highest compared with lowest quintile)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: DASH diet (highest compared with lowest quintile)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Higher fruit consumption (highest compared with lowest quintile)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Low-fat dairy products (highest compared with lowest quintile)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pro-vegetarian dietary pattern
Number of subjects: 101
Study: 36450482

Group type: EXPERIMENTAL
Intervention: Walking exercise with HTS (Hybrid Training System)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Walking exercise without HTS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Walking exercise with HTS
Number of subjects: 32
Study: 33063334

Group type: EXPERIMENTAL
Intervention: Fixed Effects (FE) estimators (gain score and deviation score estimators)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random Effects (RE) estimators (quasi-deviation score estimators)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regression or matching estimators
Number of subjects: 0
Study: 33376173

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines management
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 386
Study: 32996172

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) with scaling and root planing (SRP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-surgical therapy alone (control)
Number of subjects: 51
Study: 34185091

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) glasses during painful dressing procedures
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Wong-Baker Faces Pain Scale
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Children's Fear Scale
Number of subjects: 79
Study: 34555333

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 21 days for 16 cycles or 1 year)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Best supportive care (observation and regular scans for disease recurrence)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1005
Study: 32400354

Group type: EXPERIMENTAL
Intervention: Multiyear mass drug administration (MDA) with praziquantel, provided biannually and/or supplemented by additional interventions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T5 strategy (test–treat–track–test–treat) implemented in Egypt, Kenya, and Tanzania.
Number of subjects: 0
Study: 33607066

Group type: EXPERIMENTAL
Intervention: Tracker system with standardized language for follow-up recommendations
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Pre-intervention (no tracker system)
Number of subjects: 1036
Study: 36307187

Group type: EXPERIMENTAL
Intervention: NHF 6 L/min, FiO2 1.0
Number of subjects: 43

Group type: COMPARATOR
Intervention: NHF 0 L/min (control)
Number of subjects: 43
Study: 34618744

Group type: EXPERIMENTAL
Intervention: Structured neonatal physical therapy program (SNP), 90 minutes/day, 6 days/week until discharge
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 32997907

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 572

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 572
Study: 33397772

Group type: EXPERIMENTAL
Intervention: SB623 (2.5 × 10^6, 5.0 × 10^6, 10 × 10^6 cells)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (sham surgery)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SB623
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 35458107

Group type: EXPERIMENTAL
Intervention: Very low caloric diet (VLCD) for 6 weeks followed by a 2-week weight-maintenance period
Number of subjects: 54
Study: 33471439

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 40% of maximum inspiratory pressure (MIP) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 0
Study: 35131178

Group type: EXPERIMENTAL
Intervention: Virtual training for INR self-testing
Number of subjects: 33683

Group type: COMPARATOR
Intervention: In-Person training for INR self-testing
Number of subjects: 33683
Study: 33267922

Group type: EXPERIMENTAL
Intervention: Grocery Purchase Quality Index (GPQI) scores (mean 54.8%)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Healthy Eating Index (HEI) scores (baseline: 73.2%, 3 months: 72.4%)
Number of subjects: 209
Study: 33297831

Group type: EXPERIMENTAL
Intervention: Vinegar drink (two tablespoons vinegar in a cup of water; 3.6 g acetic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial vinegar pill (control, 0.045 g acetic acid)
Number of subjects: 0
Study: 33027560

Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 699
Study: 35708015

Group type: EXPERIMENTAL
Intervention: Gas stove and fuel during pregnancy
Number of subjects: 3195

Group type: COMPARATOR
Intervention: Solid fuels (control)
Number of subjects: 3195

Group type: EXPERIMENTAL
Intervention: Higher exposure to household air pollution
Number of subjects: 3195
Study: 34090183

Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sevoflurane-based inhalation anesthesia
Number of subjects: 102
Study: 32424576

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Changes in urologic therapy
Number of subjects: 35
Study: 33504249

Group type: EXPERIMENTAL
Intervention: SUMM intervention (n = 31)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Wait-list control group (n = 25)
Number of subjects: 56
Study: 32870434

Group type: EXPERIMENTAL
Intervention: Arthrocentesis using Shepard's cannula and lactated Ringer's solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glucocorticosteroid (GCS) injection using 1 ml/40 mg methylprednisolone acetate
Number of subjects: 30
Study: 35594551

Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 33901450

Group type: EXPERIMENTAL
Intervention: Opening Suturing (OSu)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mini-screw Anchor (MsA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment (before disc repositioning)
Number of subjects: 84
Study: 32143666

Group type: EXPERIMENTAL
Intervention: Qualitative factors associated with loss-to-follow-up (LTFU)
Number of subjects: 49
Study: 34989159

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day) in addition to usual care
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 133
Study: 34782018

Group type: EXPERIMENTAL
Intervention: Walking fOR Health (WORtH) multi‐component behaviour change intervention (education, goal-setting, self-monitoring)
Number of subjects: 60

Group type: COMPARATOR
Intervention: One-off education session
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Walking fOR Health (WORtH) multi‐component behaviour change intervention
Number of subjects: 60
Study: 33380481

Group type: EXPERIMENTAL
Intervention: Survey data from the Health and Housing in Transition study and the At Home/Chez Soi study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Count models
Number of subjects: 0
Study: 34048679

Group type: EXPERIMENTAL
Intervention: Eight cycles of eBEACOPP
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Eight cycles of rituximab plus eBEACOPP
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Six cycles of eBEACOPP
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Eight or six cycles of eBEACOPP
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Four cycles of eBEACOPP
Number of subjects: 1945
Study: 32066504

Group type: EXPERIMENTAL
Intervention: Amantadine sulphate (PK‐Merz®; twice 100 mg orally daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 36
Study: 35505326

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day) alone
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Calcium (600 mg) alone
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day) combined with Calcium (600 mg)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 545
Study: 33272643

Group type: EXPERIMENTAL
Intervention: Controlled-release pregabalin (GLA5PR GLARS-NF1 tablets)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Immediate-release pregabalin capsule
Number of subjects: 352
Study: 35659231

Group type: EXPERIMENTAL
Intervention: Passive transfluthrin emanator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 36245417

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 158
Study: 33691667

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) intervention
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 434
Study: 32778434

Group type: EXPERIMENTAL
Intervention: Group choir singing
Number of subjects: 31
Study: 36658521

Group type: EXPERIMENTAL
Intervention: Baby box group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diaper bag group
Number of subjects: 100
Study: 33884414

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Self‐directed weight loss
Number of subjects: 121

Group type: COMPARATOR
Intervention: Coach‐directed weight loss
Number of subjects: 121
Study: 32073415

Group type: EXPERIMENTAL
Intervention: Stop sign position (shoulder abducted and externally rotated to 90°, elbow flexed to 90°)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 62
Study: 34364814

Group type: EXPERIMENTAL
Intervention: Panitumumab followed after progression by regorafenib
Number of subjects: 214

Group type: COMPARATOR
Intervention: Reverse sequence (regorafenib followed by panitumumab)
Number of subjects: 214
Study: 32500717

Group type: EXPERIMENTAL
Intervention: Acamprosate (two tablets of 333 mg/d, three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (two tablets, three times a day)
Number of subjects: 20
Study: 35267992

Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 90
Study: 35005013

Group type: EXPERIMENTAL
Intervention: nalbuphine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: oxycodone
Number of subjects: 124

Group type: COMPARATOR
Intervention: morphine
Number of subjects: 124
Study: 36318924

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive approaches (including LRH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (ARH)
Number of subjects: 0
Study: 33368929

Group type: EXPERIMENTAL
Intervention: Problem-solving and Story-bridge based mental health literacy programme
Number of subjects: 25
Study: 36291340

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 12
Study: 35545297

Group type: EXPERIMENTAL
Intervention: Singing for Lung Health (SLH)
Number of subjects: 108
Study: 36036644

Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with physical therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS combined with physical therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dual tDCS combined with physical therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham tDCS combined with physical therapy
Number of subjects: 82
Study: 34373303

Group type: EXPERIMENTAL
Intervention: Behavioural Insights principles for public programme communication
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 2003
Study: 34154492

Group type: EXPERIMENTAL
Intervention: SUPR (web-based support program including booklet and online videos)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Care as usual (no support)
Number of subjects: 130
Study: 34096381

Group type: EXPERIMENTAL
Intervention: Nutrition education and counseling intervention (details on dosage and duration not specified)
Number of subjects: 438
Study: 35428720

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 175
Study: 34606332

Group type: EXPERIMENTAL
Intervention: Zoliflodacin 2 g (therapeutic)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Zoliflodacin 4 g (supratherapeutic)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive comparator)
Number of subjects: 72
Study: 36264894

Group type: EXPERIMENTAL
Intervention: FIFA 11+ programme (F11+)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Modified warm-up programme (M11+)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (routine warm-ups)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FIFA 11+ programme (F11+) and Modified warm-up programme (M11+)
Number of subjects: 90
Study: 32648790

Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 35007899

Group type: EXPERIMENTAL
Intervention: Peppermint essential oil inhalation (100% peppermint essential oil, 1 hour duration)
Number of subjects: 64